VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2019 | Sym015: MET antibody mixture for advanced solid tumors

Ross Camidge, MD, PhD, University of Colorado, Denver, CO, discusses the phase 1a/2a trial of Sym015, a MET antibody mixture, in patients with advanced solid tumors. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter